Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: GlobalData
$125.00
Provider: New Constructs, LLC
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Edwards Lifesciences Corp reaffirms FY 2014 guidance; gives Q1 2014 guidance in line with analysts' estimates


Monday, 3 Feb 2014 04:00pm EST 

Edwards Lifesciences Corp:Says that it continue to expect fiscal 2014 total sales of $2.05 billion to $2.25 billion.Says excluding special items, the company continue to expect diluted earnings per share (EPS )to be a wide range around $3.00.Says for the first quarter of 2014, it project total sales, excluding the impact of the THV reserve, of $500 million to $550 million.Sees first quarter 2014 diluted earnings per share, excluding the renewal of the research and development tax credit and other special items, to be between $0.61 and $0.71.Fiscal 2014 revenue of $2.16 billion and EPS of $3.07 - Thomson Reuters I/B/E/S.First quarter of 2014 revenue of $526 million and EPS of $0.71 - Thomson Reuters I/B/E/S.